Systemic delivery of antagomirs during blood-brain barrier disruption is disease-modifying in experimental epilepsy

Oligonucleotide therapies offer precision treatments for a variety of neurological diseases, including epilepsy, but their deployment is hampered by the blood-brain barrier (BBB). Previous studies showed that intracerebroventricular injection of an antisense oligonucleotide (antagomir) targeting mic...

Descripción completa

Detalles Bibliográficos
Autores principales: Reschke, Cristina R., Silva, Luiz F.A., Vangoor, Vamshidhar R., Rosso, Massimo, David, Bastian, Cavanagh, Brenton L., Connolly, Niamh M.C., Brennan, Gary P., Sanz-Rodriguez, Amaya, Mooney, Catherine, Batool, Aasia, Greene, Chris, Brennan, Marian, Conroy, Ronan M., Rüber, Theodor, Prehn, Jochen H.M., Campbell, Matthew, Pasterkamp, R. Jeroen, Henshall, David C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178478/
https://www.ncbi.nlm.nih.gov/pubmed/33609732
http://dx.doi.org/10.1016/j.ymthe.2021.02.021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178478/
https://www.ncbi.nlm.nih.gov/pubmed/33609732
http://dx.doi.org/10.1016/j.ymthe.2021.02.021

Ejemplares similares